Marstacimab for the treatment of haemophilia A and haemophilia B

Marstacimab is in clinical development for the treatment of adults or adolescents with severe haemophilia A, and moderately severe to severe haemophilia B. Haemophilia is a rare, inherited condition that slows blood clotting. There are two main types of haemophilia: haemophilia A (a deficiency in clotting factor VIII) and haemophilia B (a deficiency in clotting factor IX). Haemophilia is categorised as mild, moderate, and severe, based on the percentage of available clotting factors in the blood. Moderate haemophilia results in bruising easily, internal bleeding around joints, joint pain and stiffness. Severe haemophilia can result in spontaneous bleeding of nose, gums, joints, and muscles. Without treatment people with severe haemophilia can develop joint deformities, soft tissue bleeding and serious internal bleeding. Some people with haemophilia can form an immune response to current treatment options therefore alternative treatment options are needed.
Marstacimab